Literature DB >> 207740

Alteration of the growth of cytomegalovirus and herpes simplex virus type 1 by epidermal growth factor, a contaminant of crude human chorionic gonadotropin preparations.

G E Knox, D W Reynolds, S Cohen, C A Alford.   

Abstract

Pretreatment (12-48 h) of human fibroblasts with crude, human chorionic gonadotropin (HCG) was found to suppress cytomegalovirus infection and enhance productive herpes simplex type 1 (HSV) infection in vitro. Maximal effect on virus replication occurred at the time of maximal infectivity of control cultures (48 h and 6 days after viral innoculation for HSV and cytomegalovirus, respectively). The alteration in viral growth was not due to the HCG itself, but rather to epidermal growth factor, a contaminant of crude HCG. The effect of epidermal growth factor on viral infectivity was shown to be a cell-mediated event requiring protein synthesis.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 207740      PMCID: PMC372690          DOI: 10.1172/JCI109084

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  15 in total

1.  Cervical cytomegalovirus excretion in pregnant and nonpregnant women: suppression in early gestation.

Authors:  S Stagno; D Reynolds; A Tsiantos; D A Fuccillo; R Smith; M Tiller; C A Alford
Journal:  J Infect Dis       Date:  1975-05       Impact factor: 5.226

2.  Demonstration of a cellular inhibitor of Epstein-Barr and cytomegalovirus synthesis.

Authors:  R Glaser; J Zimmerman; S St Jeor; F Rapp
Journal:  Virology       Date:  1975-03       Impact factor: 3.616

3.  Cytomegalovirus replication in cells pretreated with 5-iodo-2'-deoxyuridine.

Authors:  S St Jeor; F Rapp
Journal:  J Virol       Date:  1973-06       Impact factor: 5.103

4.  Association of cervical cytomegaloviruses with venereal disease.

Authors:  M C Jordan; W E Rousseau; G R Noble; J A Steward; T D Chin
Journal:  N Engl J Med       Date:  1973-05-03       Impact factor: 91.245

5.  Recovery of cytomegalovirus from the cervix in pregnancy.

Authors:  R Montgomery; L Youngblood; D N Medearis
Journal:  Pediatrics       Date:  1972-04       Impact factor: 7.124

6.  Plaque assay of cytomegalovirus strains of human origin.

Authors:  B B Wentworth; L French
Journal:  Proc Soc Exp Biol Med       Date:  1970-11

7.  Characterization of the binding of 125-I-labeled epidermal growth factor to human fibroblasts.

Authors:  G Carpenter; K J Lembach; M M Morrison; S Cohen
Journal:  J Biol Chem       Date:  1975-06-10       Impact factor: 5.157

8.  Evidence for early nuclear antigens in cytomegalovirus-infected cells.

Authors:  L Geder
Journal:  J Gen Virol       Date:  1976-08       Impact factor: 3.891

9.  Primary infection with human cytomegalovirus: virus isolation from healthy infants and pregnant women.

Authors:  Y Numazaki; N Yano; T Morizuka; S Takai; N Ishida
Journal:  Am J Epidemiol       Date:  1970-04       Impact factor: 4.897

10.  Human epidermal growth factor: isolation and chemical and biological properties.

Authors:  S Cohen; G Carpenter
Journal:  Proc Natl Acad Sci U S A       Date:  1975-04       Impact factor: 11.205

View more
  5 in total

1.  Permissive cytomegalovirus infection of primary villous term and first trimester trophoblasts.

Authors:  D G Hemmings; R Kilani; C Nykiforuk; J Preiksaitis; L J Guilbert
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

2.  Effects of enhancing agents on detection of cytomegalovirus in clinical specimens.

Authors:  K St George; C R Rinaldo
Journal:  J Clin Microbiol       Date:  1994-08       Impact factor: 5.948

3.  Duodenal ulcer: does pathophysiology equal aetiology?

Authors:  K G Wormsley
Journal:  Gut       Date:  1983-09       Impact factor: 23.059

4.  Effects of bombesin on fasting bile formation.

Authors:  W J Kortz; J R Nashold; E Delong; W C Meyers
Journal:  Ann Surg       Date:  1986-01       Impact factor: 12.969

5.  The role of growth factor receptors in viral infections: An opportunity for drug repurposing against emerging viral diseases such as COVID-19?

Authors:  Hubert Hondermarck; Nathan W Bartlett; Victor Nurcombe
Journal:  FASEB Bioadv       Date:  2020-04-11
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.